Research article
Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer
Kathleen I. Pritchard, Humaira Khan, Mark Levine and The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer
CMAJ April 16, 2002 166 (8) 1017-1022;
Kathleen I. Pritchard
Dr. Pritchard is Head of Clinical Trials and Epidemiology, Toronto Sunnybrook Regional Cancer Centre, and Professor in the Department of Medicine, University of Toronto, Toronto, Ont.; Ms. Khan is Research Assistant, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ont.; Dr. Levine is Professor in the Departments of Medicine and Clinical Epidemiology and Biostatistics and is the Buffet Taylor Chair in Breast Cancer Research, McMaster University, Hamilton, Ont. Dr. Mark Levine (Cancer Care Ontario), Hamilton Regional Cancer Centre and McMaster University, Hamilton, Ont. Dr. Penny Barnes, Queen Elizabeth II Health Sciences Centre, Halifax, NS; Dr. David M. Bowman (Manitoba Cancer Treatment and Research Foundation), Manitoba Cancer Treatment and Research Foundation, Winnipeg, Man.; Dr. Judy Caines (Federal/Provincial/Territorial Advisory Committee on Health Services), Nova Scotia Cancer Centre, Halifax, NS; Dr. Jacques Cantin (Royal College of Physicians and Surgeons of Canada), Centre hospitalier de l'Université de Montréal, Montreal, Que.; Dr. Beverley Carter, Hamilton Health Sciences, Henderson General Hospital, Hamilton, Ont.; Ms. Chris Emery (Canadian Nurses Association), BC Cancer Agency, Delta, BC; Dr. Eva Grunfeld (College of Family Physicians of Canada), Ottawa Regional Cancer Centre, Ottawa, Ont.; Dr. Maria R. Hugi (Canadian Breast Cancer Network), Providence Health Care, Vancouver, BC; Dr. Alan W. Lees (Alberta Cancer Board), Cross Cancer Institute, Edmonton, Alta.; Ms. Sabina Mallard (Canadian Breast Cancer Network), consumer representative, Stratford, PEI; Dr. Mohamed Mohamed (Saskatchewan Cancer Foundation), Saskatoon Cancer Centre, Saskatoon, Sask.; Dr. Ivo A. Olivotto (BC Cancer Agency), Vancouver Island Cancer Centre and University of British Columbia, Victoria, BC; Dr. Leonard Reyno (Cancer Care Nova Scotia), Nova Scotia Cancer Centre, Halifax, NS; Dr. Carol Sawka (Cancer Care Ontario), Toronto Sunnybrook Regional Cancer Centre, Toronto, Ont.; Dr. Hugh Scarth (Atlantic Health Sciences Corporation), Saint John Regional Hospital, Saint John, NB; Ms. Jennifer Van Koeveringe (Health Canada), Cancer Division, Centre for Chronic Disease Prevention and Control, Health Canada, Ottawa, Ont.; and Dr. Timothy Whelan (Cancer Care Ontario), Hamilton Regional Cancer Centre and McMaster University, Hamilton, Ont.
Humaira Khan
Dr. Pritchard is Head of Clinical Trials and Epidemiology, Toronto Sunnybrook Regional Cancer Centre, and Professor in the Department of Medicine, University of Toronto, Toronto, Ont.; Ms. Khan is Research Assistant, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ont.; Dr. Levine is Professor in the Departments of Medicine and Clinical Epidemiology and Biostatistics and is the Buffet Taylor Chair in Breast Cancer Research, McMaster University, Hamilton, Ont. Dr. Mark Levine (Cancer Care Ontario), Hamilton Regional Cancer Centre and McMaster University, Hamilton, Ont. Dr. Penny Barnes, Queen Elizabeth II Health Sciences Centre, Halifax, NS; Dr. David M. Bowman (Manitoba Cancer Treatment and Research Foundation), Manitoba Cancer Treatment and Research Foundation, Winnipeg, Man.; Dr. Judy Caines (Federal/Provincial/Territorial Advisory Committee on Health Services), Nova Scotia Cancer Centre, Halifax, NS; Dr. Jacques Cantin (Royal College of Physicians and Surgeons of Canada), Centre hospitalier de l'Université de Montréal, Montreal, Que.; Dr. Beverley Carter, Hamilton Health Sciences, Henderson General Hospital, Hamilton, Ont.; Ms. Chris Emery (Canadian Nurses Association), BC Cancer Agency, Delta, BC; Dr. Eva Grunfeld (College of Family Physicians of Canada), Ottawa Regional Cancer Centre, Ottawa, Ont.; Dr. Maria R. Hugi (Canadian Breast Cancer Network), Providence Health Care, Vancouver, BC; Dr. Alan W. Lees (Alberta Cancer Board), Cross Cancer Institute, Edmonton, Alta.; Ms. Sabina Mallard (Canadian Breast Cancer Network), consumer representative, Stratford, PEI; Dr. Mohamed Mohamed (Saskatchewan Cancer Foundation), Saskatoon Cancer Centre, Saskatoon, Sask.; Dr. Ivo A. Olivotto (BC Cancer Agency), Vancouver Island Cancer Centre and University of British Columbia, Victoria, BC; Dr. Leonard Reyno (Cancer Care Nova Scotia), Nova Scotia Cancer Centre, Halifax, NS; Dr. Carol Sawka (Cancer Care Ontario), Toronto Sunnybrook Regional Cancer Centre, Toronto, Ont.; Dr. Hugh Scarth (Atlantic Health Sciences Corporation), Saint John Regional Hospital, Saint John, NB; Ms. Jennifer Van Koeveringe (Health Canada), Cancer Division, Centre for Chronic Disease Prevention and Control, Health Canada, Ottawa, Ont.; and Dr. Timothy Whelan (Cancer Care Ontario), Hamilton Regional Cancer Centre and McMaster University, Hamilton, Ont.
Mark Levine
Dr. Pritchard is Head of Clinical Trials and Epidemiology, Toronto Sunnybrook Regional Cancer Centre, and Professor in the Department of Medicine, University of Toronto, Toronto, Ont.; Ms. Khan is Research Assistant, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ont.; Dr. Levine is Professor in the Departments of Medicine and Clinical Epidemiology and Biostatistics and is the Buffet Taylor Chair in Breast Cancer Research, McMaster University, Hamilton, Ont. Dr. Mark Levine (Cancer Care Ontario), Hamilton Regional Cancer Centre and McMaster University, Hamilton, Ont. Dr. Penny Barnes, Queen Elizabeth II Health Sciences Centre, Halifax, NS; Dr. David M. Bowman (Manitoba Cancer Treatment and Research Foundation), Manitoba Cancer Treatment and Research Foundation, Winnipeg, Man.; Dr. Judy Caines (Federal/Provincial/Territorial Advisory Committee on Health Services), Nova Scotia Cancer Centre, Halifax, NS; Dr. Jacques Cantin (Royal College of Physicians and Surgeons of Canada), Centre hospitalier de l'Université de Montréal, Montreal, Que.; Dr. Beverley Carter, Hamilton Health Sciences, Henderson General Hospital, Hamilton, Ont.; Ms. Chris Emery (Canadian Nurses Association), BC Cancer Agency, Delta, BC; Dr. Eva Grunfeld (College of Family Physicians of Canada), Ottawa Regional Cancer Centre, Ottawa, Ont.; Dr. Maria R. Hugi (Canadian Breast Cancer Network), Providence Health Care, Vancouver, BC; Dr. Alan W. Lees (Alberta Cancer Board), Cross Cancer Institute, Edmonton, Alta.; Ms. Sabina Mallard (Canadian Breast Cancer Network), consumer representative, Stratford, PEI; Dr. Mohamed Mohamed (Saskatchewan Cancer Foundation), Saskatoon Cancer Centre, Saskatoon, Sask.; Dr. Ivo A. Olivotto (BC Cancer Agency), Vancouver Island Cancer Centre and University of British Columbia, Victoria, BC; Dr. Leonard Reyno (Cancer Care Nova Scotia), Nova Scotia Cancer Centre, Halifax, NS; Dr. Carol Sawka (Cancer Care Ontario), Toronto Sunnybrook Regional Cancer Centre, Toronto, Ont.; Dr. Hugh Scarth (Atlantic Health Sciences Corporation), Saint John Regional Hospital, Saint John, NB; Ms. Jennifer Van Koeveringe (Health Canada), Cancer Division, Centre for Chronic Disease Prevention and Control, Health Canada, Ottawa, Ont.; and Dr. Timothy Whelan (Cancer Care Ontario), Hamilton Regional Cancer Centre and McMaster University, Hamilton, Ont.
Dr. Pritchard is Head of Clinical Trials and Epidemiology, Toronto Sunnybrook Regional Cancer Centre, and Professor in the Department of Medicine, University of Toronto, Toronto, Ont.; Ms. Khan is Research Assistant, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ont.; Dr. Levine is Professor in the Departments of Medicine and Clinical Epidemiology and Biostatistics and is the Buffet Taylor Chair in Breast Cancer Research, McMaster University, Hamilton, Ont. Dr. Mark Levine (Cancer Care Ontario), Hamilton Regional Cancer Centre and McMaster University, Hamilton, Ont. Dr. Penny Barnes, Queen Elizabeth II Health Sciences Centre, Halifax, NS; Dr. David M. Bowman (Manitoba Cancer Treatment and Research Foundation), Manitoba Cancer Treatment and Research Foundation, Winnipeg, Man.; Dr. Judy Caines (Federal/Provincial/Territorial Advisory Committee on Health Services), Nova Scotia Cancer Centre, Halifax, NS; Dr. Jacques Cantin (Royal College of Physicians and Surgeons of Canada), Centre hospitalier de l'Université de Montréal, Montreal, Que.; Dr. Beverley Carter, Hamilton Health Sciences, Henderson General Hospital, Hamilton, Ont.; Ms. Chris Emery (Canadian Nurses Association), BC Cancer Agency, Delta, BC; Dr. Eva Grunfeld (College of Family Physicians of Canada), Ottawa Regional Cancer Centre, Ottawa, Ont.; Dr. Maria R. Hugi (Canadian Breast Cancer Network), Providence Health Care, Vancouver, BC; Dr. Alan W. Lees (Alberta Cancer Board), Cross Cancer Institute, Edmonton, Alta.; Ms. Sabina Mallard (Canadian Breast Cancer Network), consumer representative, Stratford, PEI; Dr. Mohamed Mohamed (Saskatchewan Cancer Foundation), Saskatoon Cancer Centre, Saskatoon, Sask.; Dr. Ivo A. Olivotto (BC Cancer Agency), Vancouver Island Cancer Centre and University of British Columbia, Victoria, BC; Dr. Leonard Reyno (Cancer Care Nova Scotia), Nova Scotia Cancer Centre, Halifax, NS; Dr. Carol Sawka (Cancer Care Ontario), Toronto Sunnybrook Regional Cancer Centre, Toronto, Ont.; Dr. Hugh Scarth (Atlantic Health Sciences Corporation), Saint John Regional Hospital, Saint John, NB; Ms. Jennifer Van Koeveringe (Health Canada), Cancer Division, Centre for Chronic Disease Prevention and Control, Health Canada, Ottawa, Ont.; and Dr. Timothy Whelan (Cancer Care Ontario), Hamilton Regional Cancer Centre and McMaster University, Hamilton, Ont.
Table2
References
- 1.↵
- 2.↵
Clarke R, Johnson MD. Animal models. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the breast. 2nd ed. Philadelphia: Lippincott, Williams & Wilkins; 2000. p. 319-33.
- 3.↵
Clarke R, Leonessa F, Brunner N, Thompson EW. In vitro models. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the breast. 2nd ed. Philadelphia: Lippincott, Williams & Wilkins; 2000. p. 335-54.
- 4.↵
Kelsey JL. A review of the epidemiology of breast cancer. Epidemiol Rev 1979; 1: 74-109.
- 5.↵
Henderson BE, Ross R, Bernstein L. Estrogen as a cause of human cancer. Cancer Res 1988;48:246-53.
- 6.↵
Trichopolis D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 1972;48:605-13.
- 7.↵
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
- 8.↵
Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and progestin replacement. Cancer Causes Control 1999;10:253-60.
- 9.↵
Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen–progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-91.
- 10.↵
Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-32.
- 11.↵
Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: an overview of the randomized trials. Lancet 1996;348:1189-96.
- 12.↵
Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thurlimann B, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000;355:1869-74.
- 13.↵
DiSaia PJ, Grosen EA, Kurosaki T, Gildea M, Cowan B, Anton-Culver H. Hormone replacement therapy in breast cancer survivors: a cohort study. Am J Obstet Gynecol 1996;174:1494-8.
- 14.↵
Decker D, Cox T, Burdakin J, Jaiyesimi I, Pettinga J, Benitez P. Hormone replacement therapy (HRT) in breast cancer survivors [abstract]. Proc Am Soc Clin Oncol 1996;15:209.
- 15.↵
Bluming AZ, Waisman JR, Dosik GM, Olsen GA, McAndrew P, Decker RW, et al. Hormone replacement therapy (HRT) in women with previously treated primary breast cancer, update IV [abstract]. Proc Am Soc Clin Oncol 1998;17:496.
- 16.↵
Powles TJ, Hickish T, Casey S. Hormone replacement after breast cancer. Lancet 1993;342:60-1.
- 17.↵
Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, Klien MJ, McNeese M, Singletary SE, et al. Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 1999;17:1482-7.
- 18.↵
Stoll BA. Effect of lyndiol, an oral contraceptive, on breast cancer. BMJ 1967;1:150-3.
- 19.↵
Wile AG, Opfell RW, Margileth DA, Anton-Culver H. Hormone replacement therapy does not affect breast cancer outcome [abstract]. Proc Am Soc Clin Oncol 1991;10:58.
- 20.↵
Wile AG, Opfell RW, Magileth DA. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993;165:372-5.
- 21.↵
Eden JA. A case controlled study of combined continuous estrogen–progestin replacement therapy among women with a personal history of breast cancer. Menopause 1995;2:67-72.
- 22.↵
Eden JA, Wren BG, Dew J. Hormone replacement therapy after breast cancer. In: Educational book. Alexandria (VA): American Society of Clinical Oncology; 1996. p. 187-9.
- 23.↵
O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93:754-62.
- 24.↵
Marsden J, Baum M, Jurkovic D, et al. A randomized pilot study of HRT in breast cancer patients: the combined effects of tamoxifen and HRT on the endometrium. Breast 1997;6:238-43.
- 25.↵
Marsden J, Baum M, Whitehead MI, et al. A randomized trial of HRT in women with a history of breast cancer — a feasibility study [abstract]. Acta Obstet Gynecol Scand 1997;76:22.
- 26.↵
Ganz PA, Greendale G, Kahn B, O'Leary JF. Are breast cancer survivors (BCS) willing to take hormone replacement therapy (HRT)? [abstract] Proc Am Soc Clin Oncol 1996;15:102.
- 27.↵
Pritchard K, Llewellyn-Thomas HA, Lewis J, Sawka CA, Franssen E, Del Guidice L, et al. The use of a probability trade-off task (PT-OT) to assess maximal acceptable increment in risk of breast cancer recurrence (MAIRR) in order to estimate sample size for a randomized clinical trial of hormone replacement therapy (HRT) in women with a previous diagnosis of breast cancer [abstract]. Proc Am Soc Clin Oncol 1996;15:213.
- 28.↵
Loprinzi CL. Management of menopausal symptoms in breast cancer survivors. In: Educational book. Alexandria (VA): American Society of Clinical Oncology; 1996. p. 190-2.
- 29.↵
Kessel B. Alternatives to estrogen for menopausal women. Proc Soc Exp Biol Med 1998;217:38-44.
- 30.↵
Chlebowski RT. Elements of informed consent for hormonal replacement therapy in patients with diagnosed breast cancer. J Clin Oncol 1999;17:130-42.
- 31.↵
Law M, Loprinzi CL, Veeder M, Rowland K, vanHaelst-Pisani C, Abu-Ghazaleh S, et al. Double-blind crossover trial of Replens versus KY Jelly for treating vaginal dryness and dyspareunia in breast cancer survivors [abstract]. Proc Am Soc Clin Oncol 1996;15:534.
- 32.↵
- 33.↵
Barensten R, van de Weijer PH, Schram JH. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Repr Biol 1997;71:73-80.
- 34.↵
Ayton RA, Darling GM, Murkies AL, Farrell EA, Weisberg E, Selinus I, et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol 1996;103:351-8.
- 35.↵
Gabrielsson J, Wallenbeck I, Birgerson L. Pharmacokinetic data on estradiol in light of the estring concept. Acta Obstet Gynecol Scand 1996;163(Suppl):26-31.
- 36.↵
- 37.↵
- 38.↵
Loprinzi CL, Kugler JW, Sloan J, Mailliard A, LaVasseur B, Barton D, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized trial. Lancet 2000;356:2059-63.
- 39.↵
Quella SK, Loprinzi CL, Barton DL, Knost JA, Sloan JA, LaVasseur BI, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial. J Clin Oncol 2000;18:1068-74.
- 40.↵
Loprinzi CL, Michalak JC, Quella SK, O'Fallon JR, Hatfield AK, Nelimark RA, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331:347-52.
- 41.↵
Nordin BEC. Calcium and osteoporosis. Nutrition 1997;13:664-86.
- 42.↵
- 43.↵
Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate and flurouracil chemotherapy use rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997;15:1341-7.
- 44.↵
Powles TJ, McCloskey EV, Paterson AHG, Ashley S, Tidy A, Kanis J. Oral clodronate will reduce the loss of bone mineral density in women with a primary breast cancer [abstract]. Proc Am Soc Clin Oncol 1997;16:130a.
- 45.↵
Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind placebo-controlled study. J Clin Oncol 1997;15:955-63.
- 46.↵
Pritchard KI, Levine M, Walley B. Raloxifene: Handle with care [letter]. CMAJ 2001;165(2):151,153.
In this issue
Article tools
Respond to this article
Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer
Kathleen I. Pritchard, Humaira Khan, Mark Levine, The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer
CMAJ Apr 2002, 166 (8) 1017-1022;
Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer
Kathleen I. Pritchard, Humaira Khan, Mark Levine, The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer
CMAJ Apr 2002, 166 (8) 1017-1022;